撰文丨王聪 编辑丨王多鱼 排版丨水成文 癌症 是一组异质性疾病，其特征是恶性细胞不受控制地生长和扩散，逃脱了正常的检查和平衡机制。肿瘤的分子特征可用于临床干预，以实现个性化治疗。 癌症基因组图谱 （TCGA） 和国际癌症基因组联盟 （ICGC） 的大规模基因组学研究旨在编录主要的致癌基因组改变，并提供一份全面的癌症基因组特征"图 谱"。对 30 多种人类癌症的大规模队列进行广泛的基因组测序，并结合对单个癌症类型的综合分析以及全面的泛癌分析，揭示了细胞异常的非常复杂的图景，拓 展了当前对肿瘤发生机制的认识，并创新了分子诊断方法。尽管取得了这些进展，但要预测肿瘤中的基因组/表观基因组和转录组改变如何影响下游蛋白质的表达 和活性，仍颇具挑战性。 蛋白质 是细胞中的功能单位，也是大多数疗法的作用靶点。因此，仅依据基因组/表观基因组和转录组特征来选择靶向治疗，仍有改进空间。蛋白质组不仅能够拓 展我们对细胞动态分子行为的理解，帮助揭示癌症表型的形成机制，还可能改善诊断和治疗选择。然而，迄今为止，大多数癌症蛋白质组学研究都集中在单一癌 症类型上。 2025 年 5 月 29 日，阿姆斯特丹自由大学 Connie Jimen ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Anuo Youda Gene Technology (Beijing) Co., Ltd. to provide supplementary materials regarding the cancellation of certain subsidiaries and the progress of obtaining qualifications for various IVD products and services [1][2]. Group 1: Company Operations - Anuo Youda is required to explain the reasons and progress for the cancellation of Zhejiang Anuo Youda, Anwei Kang Technology, and Yiwu Inspection Institute, and whether this has a significant adverse impact on the company's business [2]. - The company is involved in the development and commercialization of IVD products based on molecular diagnostics, focusing on non-invasive prenatal testing (NIPT) kits, sequencing instruments, and bioinformatics analysis software [6]. - Anuo Youda's NIPT kits, which detect the three most common chromosomal diseases (trisomy 21, 18, and 13), received Class III medical device certification in 2017, establishing the company as one of the early leaders in the prenatal testing market in China [7]. Group 2: Market Position - According to Zhi Shi Consulting, Anuo Youda ranked third in the NIPT market in China by sample testing volume in 2023, with market shares increasing by 9.6%, 11.6%, and 12.1% in 2021, 2022, and 2023, respectively [7]. - The company's clinical sequencing solutions include self-developed IVD testing kits and related services, with clients primarily consisting of hospitals certified for prenatal diagnosis and independent medical laboratories [6]. Group 3: Regulatory Compliance - The CSRC has requested clarification on the company's compliance with foreign investment restrictions and whether its business operations align with the necessary qualifications and regulatory requirements [2][5]. - Anuo Youda must also address any administrative penalties related to violations of the Cybersecurity Law of the People's Republic of China and the progress of any required rectifications [4].

Financial Data and Key Metrics Changes - The company is focused on achieving high single-digit revenue growth and 500 basis points of margin expansion by 2027, excluding the Greater China region [30][31] - The company has made cost reductions of approximately $100 million this year and beyond to improve its financial position [24][36] Business Line Data and Key Metrics Changes - The clinical segment accounts for approximately 55% of revenue and showed strong growth in Q1, with good placements of the X platform and mid-single-digit growth in consumables [60] - The academic and government end market, which represents about 50% of revenue, has been lowered by 15% in guidance due to funding pressures [42][47] Market Data and Key Metrics Changes - The company has noted that more than 50% of its revenue comes from clinical applications, with less than 50% from academic research, indicating a significant reliance on clinical markets [44] - The company expects the long-term growth rate for the academic market to return to around 6%, but anticipates subdued growth through 2025 due to current uncertainties [46][47] Company Strategy and Development Direction - The company is transitioning to focus on end-to-end workflows and deep insights rather than solely on sequencing, aiming to drive genomics to the next level [26][30] - The strategy emphasizes customer intimacy and operational excellence, with a commitment to innovation and maintaining a competitive edge in the market [17][71] Management's Comments on Operating Environment and Future Outlook - Management acknowledged unexpected challenges in 2025, including being placed on the unreliable entity list by Chinese authorities and NIH funding challenges, but emphasized the importance of controlling what can be controlled [21][22] - The company remains optimistic about growth opportunities in the multiomics space and believes that new product introductions will drive future revenue [34][39] Other Important Information - The company is committed to maintaining a strong presence in China, despite current challenges, and sees potential long-term opportunities in the market [54][56] - The company has launched new technologies, such as Constellation, which are expected to enhance its product offerings and customer engagement [74][90] Q&A Session Summary Question: What are the company's expectations for academic growth? - Management believes that academic growth may return to the expected 6% in the future, but it is uncertain whether this will happen within the next four years [42][46] Question: How does the company plan to address competition in the clinical market? - Management emphasized the importance of innovation and customer reliance on Illumina's solutions, stating that customers recognize the value of their investments in Illumina's technology [62][66] Question: What is the company's stance on the situation in China? - Management stated that while China represents less than 5% of revenue, they are actively working to improve relations and maintain a presence in the market, viewing it as a long-term opportunity [52][54]

以下文章来源于36氪Pro ，作者海若镜 36氪Pro . 36氪旗下官方账号。深度、前瞻，为1%的人捕捉商业先机。 将于今年年中启动新一轮融资。 文 ｜ 海若镜 来源｜ 36氪Pro（ID：krkrpro） 封面来源 ｜ Pexels 36氪获悉，脑科学AI公司曦嘉医疗（NuraNavX）近日完成数千万元天使轮融资，由险峰淇云（K2 Venture Partners）投资。本轮融资主要用于进行AI脑连 接组学产品的市场推广和进一步研发等。公司将于今年年中启动新一轮融资。 脑连接组学，通过分析大脑神经元之间的连接和组网方式来研究大脑。曦嘉医疗基于脑连接组学的AI个体化脑网络图谱，可简单理解为绘制大脑GPS，与传 统的脑部成像技术不同，它揭示大脑不同区域如何相互连接形成脑网络，进而理解大脑不同区域的功能和运作机制，这对于理解复杂脑部疾病的发生机制至 关重要，并据此在国内临床治疗了超过1000例患者。 "一部分疾病，如抑郁症、自闭症、严重失眠等，并非是脑区出现器质性病变，而是因为脑功能区的连接出现异常。"曦嘉医疗CFO原泉介绍道。 基于MRI数据，曦嘉医疗将每个患者大脑划分为379个独特的脑区，并通过连接各个分区 ...

基于MRI数据，曦嘉医疗将每个患者大脑划分为379个独特的脑区，并通过连接各个分区的神经纤维束 研究和归纳了20多个重要脑功能网络。"通过独创的SCA（结构连接图谱），我们能够为每个患者生成 个性化的脑网络图谱，进而用于神经外科手术中的脑功能区保护，以及抑郁症、焦虑症等中枢神经疾病 的治疗靶区定位和精准治疗。" 现阶段，曦嘉医疗正和北京安定医院等三甲医院合作，就部分重度精神疾病的辅助诊断和治疗，开展更 大规模的临床试验，以支持进一步的前瞻性研究。 投资界5月26日消息，据36氪报道，脑科学AI公司曦嘉医疗（NuraNavX）近日完成数千万元天使轮融 资，由险峰淇云（K2 Venture Partners）投资。本轮融资主要用于进行AI脑连接组学产品的市场推广和 进一步研发等。公司将于今年年中启动新一轮融资。 曦嘉医疗基于脑连接组学的AI个体化脑网络图谱，可简单理解为绘制大脑GPS，与传统的脑部成像技术 不同，它揭示大脑不同区域如何相互连接形成脑网络，进而理解大脑不同区域的功能和运作机制，这对 于理解复杂脑部疾病的发生机制至关重要。 "商业化方面，我们已在深圳、上海建立了自营的神经调控诊所，为抑郁症、焦虑症、失 ...

36氪获悉，脑科学AI公司曦嘉医疗（NuraNavX）近日完成数千万元天使轮融资，由险峰淇云（K2 Venture Partners）投资。本轮融资主要用于进行AI脑连接 组学产品的市场推广和进一步研发等。公司将于今年年中启动新一轮融资。 脑连接组学，通过分析大脑神经元之间的连接和组网方式来研究大脑。曦嘉医疗基于脑连接组学的AI个体化脑网络图谱，可简单理解为绘制大脑GPS，与传 统的脑部成像技术不同，它揭示大脑不同区域如何相互连接形成脑网络，进而理解大脑不同区域的功能和运作机制，这对于理解复杂脑部疾病的发生机制至 关重要，并据此在国内临床治疗了超过1000例患者。 曦嘉医疗的靶点定位逻辑 "一部分疾病，如抑郁症、自闭症、严重失眠等，并非是脑区出现器质性病变，而是因为脑功能区的连接出现异常。"曦嘉医疗CFO原泉介绍道。 基于MRI数据，曦嘉医疗将每个患者大脑划分为379个独特的脑区，并通过连接各个分区的神经纤维束研究和归纳了20多个重要脑功能网络。"通过独创的 SCA（结构连接图谱），我们能够为每个患者生成个性化的脑网络图谱，进而用于神经外科手术中的脑功能区保护，以及抑郁症、焦虑症等中枢神经疾病的 治疗靶区定位 ...

导读： 布鲁克公司发布2025年Q1财报，营收增长11.0%，核心业务BSI表现强劲，但对全年持谨慎态度，受美国研究经费削减等影响，预计营收冲击1亿美元。 公司计划通过成本控制等措施缓解压力。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在全球科研与经济环境充满不确定性的背景下，Br u k e r（布鲁克）于近日发布了2 0 2 5年第一季度财报，展现出韧性与增长并存的稳健表现。 数据显示 2 0 2 5年Q1实现营收 8 . 0 1 4亿美元 ，比2 0 2 4年Q1的7 . 2 1 7亿美元 增长了11 . 0% 。本季度营收有机增长为2 . 9%，按固定汇率（CER） 计算的营收增长为1 2 . 5%。其中，来自收购的营收增长为9 . 6%，外汇换算则带来1 . 5个百分点的负面影响。 Bruke r 的 核 心 业 务 板 块 —— 科 学 仪 器 （ BSI ） 在 本 季 度 表 现 尤 为 强 劲 ， 营 收 达 7 . 4 4 5 亿 美 元 ， 同 比 增 长 1 4 . 3% ， 有 机 营 收 增 长 5 . 1 ...

Core Insights - The research team successfully analyzed the genetic structure of global snow leopard populations, revealing low genetic diversity and survival strategies for long-term persistence [1][2] - The study is the most comprehensive genomic research on snow leopards to date, involving collaboration with multiple institutions and experts [1] Group 1: Genetic Structure and Population Division - Global snow leopards can be divided into two major genetic lineages: northern and southern lineages, with the northern lineage primarily found in Mongolia, Russia, Tajikistan, and Xinjiang, China, while the southern lineage is mainly in Tibet, Qinghai, Sichuan, and Gansu [1] - A high-quality reference genome for a female snow leopard was constructed, and whole-genome resequencing was performed on 52 samples, including skins, tissues, and blood [1] Group 2: Evolutionary History and Genetic Diversity - The population history analysis indicates a decline in snow leopard numbers from approximately 700,000 years ago to 10,000 years ago, with both lineages experiencing significant population bottlenecks during the last glacial maximum [2] - Genetic assessments show that the northern lineage has lower genome heterozygosity and genetic diversity compared to the southern lineage, correlating with its evolutionary history and smaller effective population size [2] Group 3: Implications for Conservation - Despite facing risks of low genetic diversity and high inbreeding levels, historical population bottlenecks and inbreeding have purged harmful mutations, aiding in the survival and long-term persistence of the species [2] - The findings enhance the understanding of snow leopard evolutionary potential and adaptive evolution, providing a basis for developing scientific conservation strategies [2]

方舟投资创始人伍德认为，特朗普的关税政策本质是为了减少贸易壁垒，这对股市来说是积极信号。她 上周在美中经贸关系缓和之际增持了中国科技股。 木头姐;、方舟投资（ARK Invest）创始人凯西・伍德（Cathie Wood）认为，在经历美国总统特朗普4月 关税政策引发的波动后，股市可能迎来转折点。 她周一在采访中表示，投资者开始意识到国际贸易谈判可能导向解放市场;。伍德称，她认为白宫的策 略本质是减少贸易壁垒：若最终达成这一目标，相当于减税，是积极信号。;谈及本月美英达成的贸易 协议，伍德表示希望更多协议能落地，成为美国开放市场的双向通道;。 伍德在2020年斩获153%的惊人收益，借此树立声誉并吸引了忠实跟随者。但她的长期表现令许多人对 其激进风格存疑。截至5月16日，管理规模50亿美元的ARK创新ETF五年年化回报率仅为0.59%，同期标 普500年化回报率为17.57%。 当被问及美国预算赤字膨胀问题时，伍德称相信随着技术创新加速，美国能够通过增长摆脱赤字;。其 投资基金以押注颠覆性技术闻名的伍德重申，医疗保健行业是最被低估;的人工智能（AI）应用受益 者，新工具正加速药物发现与开发。 伍德以支持AI和机 ...

今天分享的是：沙利文：2024年AI生命组学市场研究报告 报告共计：18页 一、行业定义与核心特征 AI生命组学以多组学数据为基础，通过AI算法实现数据的高效管理与挖掘、多维度整合分析及疾病机理解析。其关键特征包 括： - 数据智能处理：针对临床队列数据的高维度、高噪声特性，AI技术可自动完成降维、去噪和特征选择，优化专病队列设计，加 速生物标志物发现。 - 多组学整合分析：整合DNA测序、RNA表达谱、代谢物谱等多源数据，通过算法融合不同层面信息，揭示基因调控网络与代 谢途径的动态关联。 - 疾病与药物研究赋能：在致病机理研究中，AI通过对比患者与健康个体数据识别分子标志物；在药物开发中，支持靶点发现、 抗体优化及虚拟筛选，显著缩短研发周期。 - 个性化医疗应用：基于患者组学数据与临床病史，AI提供定制化治疗方案，覆盖肿瘤免疫疗法、罕见病诊断等领域，提升治疗 精准度。 二、市场分类与产业链布局 AI生命组学市场分为五大核心领域： 1. AI队列数据中心解决方案：智能化管理临床数据与样本，优化患者招募和试验设计，提升研究效率。 《2024年AI生命组学市场研究报告》核心内容总结 AI生命组学作为生命科学与人工 ...